XENON PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $28.44 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $28.44M, a 6.51% decline from fiscal 2024.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $30.42M, a 109.39% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $14.53M, a 26.08% decline from fiscal 2022.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $19.65M, a 73.81% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $28.44M 10-K · filed 2026-02-26 |
| 2024-12-31 | $30.42M 10-K · filed 2026-02-26 |
| 2023-12-31 | $14.53M 10-K · filed 2026-02-26 |
| 2022-12-31 | $19.65M 10-K · filed 2025-02-27 |
| 2021-12-31 | $11.31M 10-K · filed 2024-02-29 |
| 2020-12-31 | $1.53M 10-K · filed 2023-03-01 |
| 2019-12-31 | $1.59M 10-K · filed 2021-03-01 |
| 2018-12-31 | $1.03M 10-K · filed 2020-03-09 |
| 2017-12-31 | $108.00K 10-K · filed 2019-03-06 |
| 2016-12-31 | $568.00K 10-K · filed 2018-03-07 |
| 2015-12-31 | $2.43M 10-K · filed 2018-03-07 |
| 2014-12-31 | $23.00K 10-K · filed 2017-03-08 |
| 2013-12-31 | $37.00K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |